Since the excessive activation of MERTK-mediated signaling pathways is involved in EGFR-TKI resistance in NSCLC, the combination of MERTK inhibitors and anti-PD-1/PD-L1 agents may shed light on overcoming EGFR-TKI resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.